CureVac recordsdata expanded patent lawsuit towards Pfizer/BioNTech over mRNA know-how

CureVac recordsdata expanded patent lawsuit towards Pfizer/BioNTech over mRNA know-how

Could 19 (Reuters) – CureVac NV mentioned on Friday it had filed an expanded patent infringement declare towards Pfizer Inc (PFE.N) and BioNTech over using mRNA know-how and {that a} U.S. court docket had granted its request to switch the trial.

The corporate mentioned it filed a counterclaim alleging that Pfizer and its German companion BioNTech infringed on 9 of its patents, broader than its unique declare of three patents.

In July 2022, CureVac had filed a patent lawsuit towards BioNTech over using mRNA know-how within the firms’ COVID-19 vaccine.

The switch of the trial to the Japanese District of Virginia from the Federal District Court docket of Massachusetts is predicted to speed up progress of the case and permit for a probable 2024 trial date, CureVac mentioned on Friday.

Pfizer and BioNTech didn’t instantly reply to requests for remark.

Pfizer and BioNTech in response had filed a grievance with the U.S. District Court docket in Massachusetts, in search of a judgment that they didn’t infringe U.S. patents held by CureVac.

The businesses have beforehand instructed the court docket that their COVID vaccine Comirnaty doesn’t work in the identical manner as CureVac’s patented know-how.

Pfizer and BioNTech are additionally going through patent infringement lawsuits from different firms.

Reporting by Raghav Mahobe in Bengaluru

Our Requirements: The Thomson Reuters Belief Ideas.